Antipsychotic drugs
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
First Episose Psychosis
Conditions
First Episose Psychosis, Metabolic Disease, Psychosis; Episode
Trial Timeline
Nov 1, 2024 → Jun 1, 2027
NCT ID
NCT06651112About Antipsychotic drugs
Antipsychotic drugs is a pre-clinical stage product being developed by Brain Biotech for First Episose Psychosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06651112. Target conditions include First Episose Psychosis, Metabolic Disease, Psychosis; Episode.
What happened to similar drugs?
3 of 7 similar drugs in First Episose Psychosis were approved
Approved (3) Terminated (1) Active (4)
🔄HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
🔄Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
3
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06651112 | Pre-clinical | Recruiting |
Competing Products
12 competing products in First Episose Psychosis